Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: The Prospective Evaluation of Dalteparin Efficacy for Prevention of Venous Thromboembolism in Immobilized Patients Trial (the PREVENT study)

Vascular Medicine

Volumn 7, Issue 4, 2002, Pages 269-273

  Vaitkus, Paul T ^a   Leizorovicz, A ^b   Goldhaber, S Z ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

Dalteparin; Deep vein thrombosis; Prophylaxis; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ECHOGRAPHY; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; IMMOBILIZATION; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MULTICENTER STUDY; PATIENT MONITORING; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; DOUBLE-BLIND METHOD; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; IMMOBILIZATION; PATIENT SELECTION; PROSPECTIVE STUDIES; RESEARCH DESIGN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0036981434     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x02vm449oa     Document Type: Article

References (14)

1. Cohen AT. Venous thromboembolic disease management of the non-surgical moderate- and high-risk patient. Semin Hematol 2000; 37 (suppl 5): 19-22.
2. Bergqvist D, Burmark US, Flordal PA et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496-501.
3. Bergqvist D, Burmark US, Frisell J et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: A comparison with low-dose heparin. Semin Thromb Hemost 1990; 16(suppl): 19-24.
4. Erikkson BI, Kalebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991; 73-A: 484-93.
5. Hull RD, Pineo GF, Francis C et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000; 160: 2208-15.
6. Geerts WH, Heit JA, Clagett PG et al. Prevention of venous thromboembolism. Chest 2001; 119 (Suppl): 132S-75S.
7. Mismetti P, Laporte-Simitsidis S, Tardy B et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-19.
8. Samana MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely Ill medical patients. N Engl J Med 1999; 341: 793-800.
9. The PIOPED investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Result of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990; 263: 2753-59.
10. Prentice CR. Are symptomatic endpoints acceptable in venous thromboprophylactic studies? Haemostasis 1998; 28 (suppl 3): 109-12.
11. Dh Te R, Pellicer-Coeuret M, Belouet-Moureau C, Christoforov B, Vidal-Trecan G. Venous thromboembolism in medical inpatients: Prophylaxis with low-weight heparin in a university hospital and prevalence of thromboembolic events. Clin Appl Thromb Hemost 2001; 7: 16-20.
12. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Ann Intern Med 2000; 133: 464-70.
13. Emmanuel EJ, Miller FG. The ethics of placebo-controlled trials - A middle ground. N Engl J Med 2001; 345: 915-19.
14. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129: 1044-49.